Progress in detection and technology applications of minimal residual disease detection in postoperative early stage non-small cell lung cancers

VernacularTitle:早期非小细胞肺癌术后微小残留病灶检测技术与应用进展
Author: Ruiqi NIU ¹ ; Pingping LIU ; Yingying DU
Author Information

1. 安徽医科大学第一附属医院肿瘤科，合肥　230022
Keywords: Carcinoma, non-small-cell lung; Clinical study; Minimal residual disease; Detection technology
From: Journal of International Oncology 2022;49(10):623-626
CountryChina
Language:Chinese
Abstract: Surgery is the mainstay of treatment for early lung cancers, but there is still a risk of recurrence and metastasis after surgery. With the advancement of molecular biology and detection methods, detecting the level of postoperative peripheral blood minimal residual disease (MRD) in patients can dynamically monitor recurrence and determine prognosis. Due to the wide variety of MRD detection methods, uneven detection power, lack of uniform standards and prospective study validation, clinical application is still controversial. The further development of MRD detection for early stage cell lung cancer still needs technical progress, standardized detection criteria and credible clinical data.